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ABSTRACT 
 
Chronic kidney disease is a long term condition characterised by the gradual loss of kidney function at least 
a period of 3 months or more. About two-third of the cases are mainly caused due to HTN and DM. The 
symptom load plays a crucial role in the patient's disease experience and among the main signs of CKD are 
troubling physical and psychological symptoms. The evaluation of the symptom burden of CKD patients is 
of the utmost importance in clinical management. The risk factors include age, sex, race and ethnicity, family 
history, drug use, smoking, and socioeconomic status; and other comorbidities, such as hypertension and 
diabetes. Some risk factors can be modified and prevent or slow down the progression to ESRD. CKD pro-
gression is associated with serious complications such as cardiovascular risk, dyslipidemia, anemia, nutri-
tional issues, and mineral and bone disorders. 
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INTRODUCTION 
In normal people, the kidneys, weighing about 4 
ounces each, filters about 200 litres of blood daily to 
remove waste products and excess water. Renal me-
tabolizes 25-hydroxyvitamin D to calcitriol, which is 
an active ingredient, controls calcium absorption 
from foods taken and facilitates bone formation. They 
are essential for the development of erythropoietin, 
which promotes the synthesis of erythrocytes via the 
bone marrow. A hormone called renin is secreted by 
juxtaglomerular kidneys, which helps control blood 
volume and blood pressure. Whilst dialysis can re-
place some kidney functions, it cannot mimic the nor-
mal kidney function's biosynthetic and metabolic ac-
tivities.[1] 
Chronic kidney disease: In 2002, the US NKF KDOQI 
clinical practice guidelines defined chronic kidney 
disease as renal failure or glomerular filtration rate 
lower than 60 mL/min per 1·73 m² for a period of 3 
months or more, and developed a system to classify 
based on the estimated glomerular filtration rate.[2] 
CKD staging 
Evaluation and justification for the measures of CKD 
severity, and the NKF created standards as a feature 
of its K/DOQI to stratify CKD patients: 
Stage 1: normal eGFR 90 mL/min/1.73 m2 and con-
stant albuminuria 
Stage 2: eGFR 60- 89 mL/min/1.73 m2 
Stage 3: eGFR 30- 59 mL/min/1.73 m2 
Stage 4: eGFR 15 - 29 mL/min/1.73 m2 
Stage 5: eGFR below 15 mL/min/1.73 m2 or end-
stage renal disease.[3] 
Epidemiology 
CKD has developed into a potential risk factor for 
global morbidity and death. Earlier, in developing 
countries it was perceived as a major health concern 
with 4 out of 5 cases of death from chronic kidney dis-
ease occurring in low to average income countries. 
The death rate will rise from 3.78 million in 1990 
(40.4% of all deaths) to 7.63 million in 2020 (66.7% 
of all deaths) in india.[4] 
In America around 1 in 9 adults have CKD and a mi-
nority suffer from their terminal condition, ESRD.[3, 5] 
In America the prevalence of CKD stages is as follows: 
1.8 percent of stage 1, 3.2 percent of stage 2, 7.7 per-
cent of third stage, and 0.35 percent of stage 4 and 5. 
Patients with stage 3 or 4 illnesses can advance to 
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stage 5 at a rate of 1.5% per annum. Phase 1 or 2 de-
velop into more advanced stages of CKD at around 0.5 
percent per year.[6] 
Symptoms: Symptom burden plays a central role in 
the patient's experience of the disease and trouble-
some physical and psychological symptoms are 
among the main manifestations of CKD. The typical 
symptoms are fatigue, pruritus, irritability, anxiety, 
and nausea. Assessment of the symptom burden of all 
CKD patients is very essential in clinical management. 
However, evidence reveals that healthcare profes-
sionals frequently under recognize and under-treat 
the physical symptoms, with patients subsequently 
experiencing immense physical and physiological 
trauma.[7] 
Risk factors: It is important to identify individual 
predisposing factors for CKD in terms of personal and 
community health, since such risk factors can be 
changed and avoided or the objective is to analyse 
lifestyle factors such as age, sex, race and ethnicity, 
family history, medication use, smoking, socioeco-
nomic status; and other co-morbidities such as high 
blood pressure, high blood glucose levels.[8] are men-
tioned in (Table 1) 
Table 1: Risk Factors 
Non Modifiable risk factors Modifiable risk factors 
Family History 
Gender 
Age 
Race 
Ethnicity 
Low birth weight 
Obesity 
Smoking 
Nephrotoxins 
Hypertension 
Diabetes 
Family history: CKD patients' family history has an 
elevated incidence of CKD and its risk factors. Hered-
itary conditions and urological causes involve almost 
23% of patients with incident dialysis who had imme-
diate relatives with ESRD.[9] 
Gender: Many registries like the Japanese Society for 
Dialysis Therapy have illustrated that   ESRD is more 
common among men.[10] In contrast, the CREDIT 
study demonstrated that CKD is higher in women 
than in men (18.4 vs. 12.8%) in Turkey.[11] 
Ethnicity: Several findings in the US have proved that 
there is higher risk of developing ESRD in African 
Americans relative to Caucasians.[12] The risk of hy-
pertensive ESRD is nearly five times higher in African 
Americans.[13] Recent findings reported that the life-
time risk of developing ESRD was found to be 7.8 per-
cent for 20-year-old black women, 7.3 percent in case 
of black men, 1.8 percent in case of white women, and 
2.5 percent for white men.[8] 
Age: Renal function drops dramatcally with age in 
both men and women. Amongst the elderly popula-
tion, more than one-half of the subjects diagnosed 
with CKD stages 3-5 (GFR 60 ml/min per1.73 m2) 
were recognised by the National Kidney Foundation 
Kidney Disease Outcomes Quality   Initiative 
(K/DOQI) guidelines.10 Thus, the elderly population 
more likely prone to develop CKD after various renal 
injuries.[14, 15]  
In the 1980s, Brenner and his colleagues proposed 
that restriction of intrauterine growth could lead to 
low counts of nephrons, which may cause high blood 
pressure and renal dysfunction (also known as the 
Barker hypothesis). 
Low birth weight: In the 1980s, Brenner and his col-
leagues proposed that restriction of intrauterine 
growth could lead to low counts of nephrons, which 
may cause high blood pressure and renal dysfunction 
(also known as the Barker hypothesis).[16] Nephron 
count have been appeared to increase by 257.426 glo-
meruli per kg of birth weight in assistance of this the-
ory.[17] Low counts of nephrons contribute to intra-
glomerular hypertension and hyperfiltration in the 
available nephrons and lower over-all GFR and in-
creased albumin-to-creatinine ratio in urine. Re-
duced birth weight and restrictions on intrauterine 
growth were positively correlated with higher risk of 
ESRD among Norwegians.[18] 
Obesity: Obesity was among the most modifiable pri-
mary factors causing the ESRD in the 21st era. Glomer-
ular hypertrophy and hyperfiltration increase renal 
injury by increasing the capillary wall tension of the 
glomeruli and lowering the density of the podo-
cyte.[19] Obesity can lead to pathogenesis of CKD by 
inflammatory mediators, , prothrombotic condition, 
hypervolemia, oxidative stress, dysfunction of endo-
thelium, and  adipokine derangements.[20] Apart from 
increased BMI, increased weight round the abdomen 
was linked with greater risk of CKD.[21] 
 Socioeconomic status: Socioeconomic status may 
be determined by income, occupation, education, 
wealth, and housing situation.[22] 
Smoking: Smoking enhances CKD risk through oxi-
dative stress, by endothelial dysfunction, glomerulo-
sclerosis, proinflammatory state, tubular atrophy and 
prothrombotic shift.[20] 
Nephrotoxins: Alcohol and recreational medicinal 
products were related to CKD development as well as 
improper use of analgesic medicinal products and ex-
posure to heavy metals.23 Patients consuming less 
than a thousand paracetamol medicinal products 
were used for comparison, the odds ratio for ESRD 
was found to be 2.0., for  those  who  had  taken 1000 
– 4999  tablets, and  2.4  for  those  who  had  taken  
5000  or more tablets.[24] 
Diabetes Mellitus: Diabetes mellitus (DM) is the pri-
mary CKD and ESRD etiology in both developed and 
still developing countries.[25] Mechanisms contrib-
uting to diabetes kidney disease include hyperfiltra-
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tion damage, advanced end products for glycosyla-
tion, and ROS (reactive oxygen species). At the molec-
ular level, growth factors, various cytokines, hor-
mones such as the growth factor-beta and angioten-
sin II transformation induce pathological changes re-
lated to diabetic nephropathy.[26] 
Hypertension: Hypertension has long been a etiol-
ogy of kidney impairment and constitutes 27% of all 
patients with ESRD in America and 28% of patients 
with hemodialysis in Turkey.[27] Systemic hyperten-
sion due to intraglomerular capillary tension leading 
to glomerulosclerosis and loss of kidney function; a 
transient risk of diminished renal function was docu-
mented in hypertensive subjects. Important hyper-
tension is found in age groups of 25 to 45 years, but 
kidney impairment does not occur unless the subject 
has minimum 10 years of uncontrolled hyperten-
sion.[26] Major risk conditions for CKD include previ-
ous experience of, hepatitis C virus, hyperlipidemia, 
human immunodeficiency virus infection, cardiovas-
cular disease, malignancy and  metabolic syndrome. 
Newly defined Risk Factors: Obstructive sleep ap-
nea is a condition that has been correlated with total 
and partial breathing difficulties during sleep for 
minimum five events per hour. Also proposed as a 
causal factor for CKD was heart rate. Patients with el-
evated heart rate are more likely to have lower aver-
age GFR and increased risk of developing pro-
teinuria.[28] 
Gram-negative tooth-associated bacterial biofilms 
have also identified periodontal disease as a causal 
factor for CKD. In such patients the inflammatory re-
sponse is associated with renal disease.[29] 
CKD complications and its management 
CKD associated anemia: Anemia is described as a 
significant reduction in one or more of the main red 
blood cells measurements hemoglobin levels, packed 
cell volume, or red blood corpuscle count. Optimal he-
moglobin level in men and postmenopausal women is 
below 13 g/dL, and in premenopausal women below 
12 g/d.[30] Normochromic, normocytic anemia gener-
ally related to progressive CKD,[31] and thus total 
prevalence of CKD-related anemia is around 50%. 
Although anemia are often diagnosed in any stage of 
CKD patients, the prevalence of anemia and   severity 
of disease are strongly interlinked. One-fourth of pa-
tients experiencing from stage 1 CKD; half of CKD pa-
tients with stage 2, 3, and 4; and three-quarters of di-
alysis-initiated CKD patients (stage 5) experience 
anemia.[32] 
Anemia in renally ill-patients may results from many 
processes (iron, folate, or vitamin B12 insufficiency; 
gastrointestinal bleeding; significant hyperparathy-
roidism; systemic inflammation; and decreased red 
blood cell survivability), reduced erythropoietin for-
mation is more important and specific etiological fac-
tor that contributes to anemia in CKD patients. Eryth-
ropoietin produced by the interstitial renal fibro-
blasts[33] is required in the bone marrow for red blood 
cells to grow and differentiate. In CKD, tubular atro-
phy tends to cause tubulointerstitial fibrosis, which 
compromises synthetic ability of renal erythropoietin 
and results in anemia. 
The CKD related anemia is treated by recombinant 
human erythropoietin (EPO). This technique re-
placed transfusions as the primary therapy and im-
proved the survival rates in CKD patients with ane-
mia.[34] 
CKD associated mineral and bone disorders 
The phrase ''CKD associated mineral and bone disor-
ders'' involves defects of bone and mineral metabo-
lism and/or extraskeletal calcification secondary to 
CKD pathophysiology.[35, 36] The kidney is the primary 
site for excretion of  phosphate and vitamin D1-a-hy-
droxylation. Patients with renal dysfunction have ex-
cessive phosphate levels due to lack of 1, 25 dihy-
droxy-vitamin D levels indicating decreased paren-
chymal synthesis. In top of this, renal phosphate ex-
cretion is decreased. Simultaneously, these pathways 
triggers serum calcium levels to decline, leading to in-
creased secretion of parathormone (secondary hy-
perparathyroidism). The parathyroid hormone has a 
phosphaturic effect. The parathormone elevates the 
serum calcium to help bone resorption and promot-
ing 1-a-hydroxylation of 25-hydroxy vitamin D syn-
thesized by the liver which is limited due to reduced 
kidney reserve from scarring. Increased phosphorus 
levels are most widely observed in stage 3 CKD pa-
tients.[37] 
The main aim of CKD-associated bone and mineral 
disorders therapy is reduction of the phosphorous 
amount. Initial treatment limits consumption of 
phosphorus through diet when the levels of phos-
phate or parathyroid hormone begin to increase. In 
chronic medical conditions, calcium-based binders 
are commonly used in the phosphate binders group 
for CKD-related hyperphosphatemia treatment, and 
as aluminum-associated toxicity have been docu-
mented in aluminum- phosphate binders (aluminium 
based). While calcium- phosphate binders may in-
duce hypercalcemia, which in particular in the pres-
ence of hyperphosphatemia increases the deposition 
of calcium in the tissue, If indicated (e.g., a patient 
with CKD with hypercalcemia), use of aluminium - 
phosphate binders for short period of time remains 
appropriate; while alternative, calcium-free, phos-
phates such as the non-absorbable sevelamer have 
been developed. This has the benefit of losing calcium 
or aluminum. 
Besides phosphate binders, many other groups of 
drugs have been established to treat the CKD-associ-
ated mineral disorder. Given the reduced 1-hydrox-
ylation of vitamin D by the injured kidney, vitamin D  
and its related compounds could also be needed to 
boost the serum calcium concentration sufficiently to 
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suppress parathyroid hormone secretion. CKD pa-
tients can also receive calcimimetics that enhance the 
calcium tolerance of the receptor sensing calcium ex-
pressed by the parathyroid gland, decrease the para-
thyroid hormone secretion and decrease parathyroid 
gland hyperplasia. 
Cardiovascular risk: The cardiovascular risk associ-
ated with ESRD has been well established, and the av-
erage cardiovascular mortality rate among dialysis 
patients is 10 to 100 times higher than among age- 
and sex-factor matched patients in the overall popu-
lation.[38] 
Hypertension is a typical risk factor for the cardiovas-
cular, contributing to cardiovascular risk correlated 
with CKD. Muntner and his colleagues have shown 
that hypertension in patients with stage 2-3 CKD are 
at elevated risk for new or recurrent cardiovascular 
problems.[39] Systolic blood pressure is more closely 
associated with cardiovascular mortality in patients 
with dialysis than pulse or diastolic pressure.[40] 
In patients with proteinuric, progressive diabetic and 
nondiabetic renal disease, angiotensin-converting 
enzyme inhibitors, or (ARB) angiotensin-receptor 
blockers, ideal first-line agents with renal protective 
effects are given.[41] 
Inflammation is a less discussed risk factor which is 
believed to have a significant role in the regulation of 
CKD related cardiovascular risk. Inflammatory recep-
tors are often elevated in CKD patients, and cardio-
vascular risk in this population is estimated. Most of 
the research work in CKD patients have documented 
that C-reactive protein levels in blood predict cardio-
vascular outcomes.[42] Proteinuria, a hallmark of re-
nal dysfunction, is associated with elevated cardio-
vascular disease risk and early cardiovascular mor-
tality in patients with and without diabetes and hy-
pertension.[43, 44] 
Dyslipidemia: CKD is strongly linked with 
dyslipidemia which consists of elevated triglycerides 
and less HDL-cholesterol. LDL-cholesterol levels 
(and, thus, overall cholesterol) are not usually in-
creased. CKD leads to lower lipoprotein lipase and 
LDL receptor control, and increased triglycerides in 
CKD are caused by delayed catabolism of lipoproteins 
rich in triglycerides, with no developmental varia-
tions.[45] CKD is positively correlated reduced levels 
of apoA-I (due to reduced hepatic activity) and ele-
vated apoB / apoA-I.46 Reduced activity of lecithin-
cholesterol acyltransferase and elevated protein 
transfer cholesterol esterol (CETP) event lead to re-
duced levels of HDL cholesterol.[47] Statins are the fre-
quently used lipid-lowering drugs are listed in (Table 
2). 
Nutritional Issues: When patients progress along 
the stages of CKD, dietary needs are altered and pro-
tein, phosphorus, sodium, potassium, water and me-
tabolism are impaired. 
Any modifications in nutrient use contributes to "ure-
mic malnutrition," a syndrome distinct from malnu-
trition caused by inadequate intake of nutrients. Eval-
uation of nutritional condition in patients with CKD is 
critical in resolving the nutritional necessity. Several 
nutritional markers can be used to evaluate nutri-
tional status. Serum albumin, marker used in all pa-
tient populations, due to its simple availability and 
close association with hospitalization and cause of 
death.[50] 
Lower levels of serum albumin are the most common 
markers of inadequate clinical results at all stages of 
CKD, and serum albumin is thus considered a reliable 
marker of general clinical status.[51] Clinical guide-
lines recommend maintaining a value of 4.0 g / dL or 
greater for serum albumin in patients with stage 5 
CKD.[52] Serum prealbumin is a sensitive marker for 
assessing the changes in visceral protein stores with 
a small body pool and fairly fast turnover of 2-3 days. 
Levels below 30 mg/dL indicate protein depletion.[53] 
Low concentrations of serum creatinine are associ-
ated with poor clinical results when treating stage 5 
CKD. The concentration of serum cholesterol is an in-
dependent indicator of mortality in chronic dialysis 
Table 2: Statin Dosing in CKD 
Statin 
Standard  dos-
age (mg/d) 
Clearance 
Dose range in 
stages  1-3 CKD 
Dose range in 
stages  4-5 CKD 
Use with cyclosporine 
Atorvas-
tatin 
10-80 Liver 10-80 10-80 Avoid in combination with 
cyclosporine 
Fluvas-
tatin 
20-80 Liver 20-80 20-40 Max dose 20 mg/d with cy-
closporine 
Lovastatin 10-80 Liver 10-80 10-20 Avoid use with cyclosporine 
Pitavas-
tatin 
1-4 Liver/Kid-
ney 
1-2 1-2 Avoid use with cyclosporine 
Pravas-
tatin 
10-80 Liver/Kid-
ney 
10-80 10-20 Maximum dose 20 mg/d 
when used with cyclosporine 
Rosuvas-
tatin 
10-40 Liver/Kid-
ney 
5-40 5-10 Max dose 5 mg/d with cyclo-
sporine 
Simvas-
tatin 
5-40 Liver 5-40 5-40 Avoid use with cyclospor-
ine.48 
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patients, and lower serum cholesterol levels can indi-
cate low dietary and energy intake. Serum cholesterol 
below 150 mg / dL also needs vigilant nutritional sta-
tus assessment.[54]  
A dietary protein intake of less than 0.75 g / kg / d is 
an early warning signal in patients with low protein 
and energy intake (as recorded in patients on uncon-
trolled diets) for acquiring uremic malnutrition. For 
CKD patients, poor nutrition may warrant initiation 
of haemodialysis or be an indication for transplant. 
Nutrient markers such as transferrin, transthyretin, 
insulin growth factor-1 are reduced and a drop in 
lean body weight. Other markers implying the neces-
sity for early haemodialysis initiation in ESRD pa-
tients involves energy consumption less than 20 kcal 
/ kg / d, and concentration of serum albumin below 
4.0 g / dL. Enteral nutrition includes oral proteins, 
amino acids and/or energy supplements; enteral de-
livery of nutrients is performed by feeding through 
nasogastric tubes or percutaneous endoscopic gas-
troscopy or jejunostomy tubes or through intradi-
alytic parental nutrition. [55] 
CONCLUSION 
Patients with CKD have many complex management 
problems to health care providers. The staging sys-
tem introduced in 2002 by the National Kidney Foun-
dation is a notable accomplishment, which classifies 
patients according to disease severity. Knowing the 
predisposing factors and screening of target popula-
tions will help to identify and facilitate early manage-
ment of modifiable risk factors for patients with 
ESRD. Development of CKD is associated with several 
complications such as anemia, dietary problems, 
dyslipidemia, cardiovascular diseases, mineral and 
bone disorders. Early detection and management by 
health providers helps in making significant strides 
toward improving the health of patients with chronic 
renal disease. 
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